citric acid; lactic acid; potassium bitartrate - Profile

What are the generic drug sources for citric acid; lactic acid; potassium bitartrate and what is the scope of freedom to operate?

Citric acid; lactic acid; potassium bitartrate is the generic ingredient in one branded drug marketed by Evofem Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Citric acid; lactic acid; potassium bitartrate has forty-six patent family members in eighteen countries.

Summary for citric acid; lactic acid; potassium bitartrate

International Patents:	46
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for citric acid; lactic acid; potassium bitartrate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for citric acid; lactic acid; potassium bitartrate

Constraining patent/regulatory exclusivity:

11,439,610

Dosage:

GEL;VAGINAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PHEXXI	Vaginal Gel	citric acid; lactic acid; potassium bitartrate	1.8%/1%/0.4%	208352	1	2023-02-28

US Patents and Regulatory Information for citric acid; lactic acid; potassium bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes	11,337,989
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes	11,992,472
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes	10,568,855
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020		RX	Yes	Yes	11,439,610		Y	Y

Expired US Patents for citric acid; lactic acid; potassium bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Evofem Inc	PHEXXI	citric acid; lactic acid; potassium bitartrate	GEL;VAGINAL	208352-001	May 22, 2020	6,706,276

International Patents for citric acid; lactic acid; potassium bitartrate

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2016129069	КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВОСПАЛЕНИЯ И ЗАБОЛЕВАНИЙ С ПРИМЕНЕНИЕМ АНТИМИКРОБНОГО СОЕДИНЕНИЯ НА ОСНОВЕ АЛЬГИНОВОЙ КИСЛОТЫ (COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND)
Japan	2022070924	アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
China	106029078
South Korea	102062599

Last updated: February 3, 2026

mmary
This report analyzes the investment scenario, market dynamics, and financial trajectory of three key pharmaceutical-grade acids: citric acid, lactic acid, and potassium bitartrate. Market trends, growth drivers, competitive landscape, and regulatory considerations are examined to guide strategic decision-making. The analysis includes current market sizes, projected growth rates, key players, applications, and future outlooks.

---

Investment Scenario for Citric Acid, Lactic Acid, and Potassium Bitartrate in Pharmaceutical Applications

Overview of Market Fundamentals

Compound	Market Size (2022)	CAGR (2023-2028)	Major Applications	Key Producers	Regulatory Environment
Citric Acid	~$1.2 billion	4.8%	Pharmaceutical excipients, buffering agents, stabilizers	ADM, Jungbunzlauer	FDA, EMA compliant
Lactic Acid	~$680 million	6.2%	Medicinal products, pH adjusters, dietary supplements	Corbion, Jungbunzlauer	Stringent pharma standards
Potassium Bitartrate	~$250 million	3.5%	Antioxidants, anti-inflammatory agents, stabilizers	Finar, Roquette	Food/pharma-grade standards

---

Market Dynamics and Drivers

What Are the Key Market Drivers?

Driver	Description	Supporting Data
Increase in Pharmaceutical Formulations	Growing demand for excipients and stabilizers in drug formulation	Market reports estimate 5-7% annual growth in pharmaceutical excipients 2023–2028[1]
Rising Chronic Diseases	Elevated use in treatments for cardiovascular, neurological, and metabolic disorders	World Health Organization reports 3-5% annual increase in relevant drug markets[2]
Consumer Shift Toward Natural and Organic	Preference for natural acids in pharmaceuticals enhances demand	Natural excipient market growth projected at 7% CAGR[3]
Regulatory Stringency	Hardening standards promote higher quality, pharmaceutical-grade supply	Increased GMP standards boost premium segment profitability

What Are the Barriers and Risks?

Barrier / Risk	Description	Mitigation Strategies
Raw Material Volatility	Prices affected by agricultural supply/demand fluctuations	Long-term contracts, diversified supplier base
Regulatory Approval Delays	Lengthy approval processes can defer market entry	Active engagement with regulatory agencies
Competition from Synthetic Alternatives	Price competition with synthetic substitutes	Focus on natural, high-purity grades
Supply Chain Disruptions	Global events affecting raw material access	Strategic inventory, multiple sourcing

---

Financial Trajectory and Investment Opportunities

Historical Revenue and Profitability Trends

Compound	2020 Revenue (USD)	2022 Revenue (USD)	CAGR (2020-2022)	Typical Profit Margins	Notable Trends
Citric Acid	~$900 million	~$1.2 billion	8.4%	12-15%	Increasing pharmaceutical segment share
Lactic Acid	~$550 million	~$680 million	8.7%	10-14%	Rising growth in pharma applications
Potassium Bitartrate	~$200 million	~$250 million	9.4%	8-12%	Moderate growth, niche market

Future Revenue Projections (2023-2028)

Compound	2023 Forecast (USD)	2028 Projection (USD)	Total CAGR	Key Assumptions
Citric Acid	~$1.25 billion	~$1.78 billion	6.1%	Expanded pharma formulations, regional growth
Lactic Acid	~$700 million	~$1.02 billion	8.5%	Increased medical, nutritional uptake
Potassium Bitartrate	~$260 million	~$330 million	4.9%	Niche applications' steady expansion

---

Competitive Landscape and Major Players

Company	Market Share (Estimated)	Core Competencies	Notable Developments
Jungbunzlauer	25%	Natural acid manufacturing, GMP standards	Expansion into pharma-grade supply chain
Archer Daniels Midland (ADM)	20%	Large-scale production, integrated supply	Strategic partnerships for pharma-grade products
Corbion	15%	Sustainable sourcing, R&D innovation	Novel lactic acid derivatives for pharma
Roquette	10%	Specialty excipients, niche markets	New product launches in pharmaceutical acids
Finar	5%	Cost leadership, regional focus	Capacity enhancement in potassium salts

---

Policy and Regulatory Considerations

Current Standards

• FDA (United States): Monographs specify purity standards for pharmaceutical acids. Good Manufacturing Practices (GMP) compliance essential.
• EMA (European Union): Emphasizes quality, traceability, and safety certifications for pharma ingredients.
• Global Harmonization: Efforts via ICH (International Council for Harmonisation) standards influence global regulation pathways.

Implications for Investors

• Regulatory approval timelines impact time-to-market and revenue recognition.
• Market entry strategies must prioritize compliance and quality assurance.
• Emerging markets seeking to align with international standards present growth opportunities.

---

Comparison of Market Suitability for Investment

Parameter	Citric Acid	Lactic Acid	Potassium Bitartrate
Market Size (2022, USD)	~$1.2 billion	~$680 million	~$250 million
Growth Rate (CAGR 2023-2028)	4.8%	6.2%	3.5%
Profit Margins	12-15%	10-14%	8-12%
Investment Attractiveness	Moderate	High	Moderate
Key Growth Drivers	Broader applications, natural preference	Medical, nutrition, niche uses	Niche, low competition

---

FAQs

1. What are the main growth drivers for pharmaceutical-grade citric acid, lactic acid, and potassium bitartrate?
The main drivers include increased demand for drug excipients, rising chronic disease treatments, consumer preference for natural products, and stringent regulatory standards encouraging high-purity production.

2. How do regulatory standards influence investment strategies in these acids?
Regulatory approval timelines and compliance requirements significantly impact market entry costs and timing. Firms investing in GMP-certified, high-quality production are better positioned to capitalize on both existing markets and emerging regions.

3. What are the key risks associated with investing in these acids?
Volatility in raw material prices, supply chain disruptions, regulatory delays, and competition from synthetic alternatives pose significant risks, requiring proactive risk management with diversified sourcing and compliance.

4. Which of the three compounds offers the highest growth potential?
Lactic acid exhibits the highest projected CAGR (6.2%), driven by expanding medical, nutritional, and industrial applications, followed closely by citric acid.

5. How do regional markets differ in terms of demand?
Developed regions (North America, EU) emphasize regulatory compliance and high-quality standards, while emerging markets present growth opportunities driven by expanding healthcare infrastructure and regulatory harmonization efforts.

---

Key Takeaways

• The pharmaceutical acids market is positioned for steady growth, with lactic acid leading in CAGR, driven by expanding applications.
• Investment opportunities are favorable in high-growth niches such as natural excipients, with potential for premium product positioning.
• Strict regulatory standards necessitate a focus on GMP certification and quality control, influencing manufacturing investments.
• Competition is intense among major players, but regional and product specialization can offer entry points.
• Diversifying raw material sourcing and emphasizing compliance can mitigate supply chain and regulatory risks.

---

References
[1] MarketsandMarkets, "Pharmaceutical Excipients Market," 2023.
[2] WHO, "Global Status Report on Noncommunicable Diseases," 2022.
[3] Grand View Research, "Natural Excipient Market," 2023.